Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript February 12, 2026 Vertex Pharmaceuticals ...

Q4 2025 Earnings Call February 10, 2026 4:30 PM ESTCompany ParticipantsJacquie Ross - Senior Vice President of Treasury ...

Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2025.

When a cell divides, it performs a feat of microscopic choreography—duplicating its DNA and depositing it into two new cells.

A research team led by UAB researcher David Reverter has discovered the molecular mechanism that describes in detail the ...

Researchers have uncovered the enzyme behind chromothripsis, a chaotic chromosome-shattering event seen in about one in four ...

Scientists at Cedars-Sinai have uncovered a surprising repair system in the spinal cord that could open new doors for treating paralysis, stroke, and diseases like multiple sclerosis. They found that ...

Joining me on today's call are our CEO, Matthew Desch and our CFO, Vincent J. O'Neill. Today's call will begin with a ...

The collaboration supports growing demand for plant-based, clean-label vitamin D3 solutions. IRVINE, CA, UNITED STATES, ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved ...

Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 –– Cabozantinib Franchise Achieved $2.123 billion in U.S. Net Product Revenues for the Fiscal ...

Inflammatory bowel disease (IBD) is typically diagnosed after the onset of symptoms in the context of established, characteristic patterns of intestinal inflammation. However, there is now substantial ...